Cookson Tyler Alexander
Department of Physiology, University of Alberta, Edmonton, AB, Canada.
Front Cardiovasc Med. 2021 Aug 13;8:721393. doi: 10.3389/fcvm.2021.721393. eCollection 2021.
Hypertension is a major risk factor for the development of cardiovascular disease. As more research into the gut microbiome emerges, we are finding increasing evidence to support that these microbes may have significant positive and negative effects on blood pressure and associated disorders. The bacterial-derived metabolites that are produced in the gut are capable of widespread effects to several tissue types and organs in the body. It is clear that the extensive metabolic function that is lost with gut dysbiosis is unlikely to be replenished with a single metabolite or bacterial strain. Instead, combinations of bacteria and concomitant therapies will provide a more well-rounded solution to manage hypertension. The bioactive molecules that are recognized in this review will inform on ideal characteristics of candidate bacteria and provide direction for future research on the gut microbiome in hypertension.
高血压是心血管疾病发展的主要风险因素。随着对肠道微生物群的研究越来越多,我们发现越来越多的证据支持这些微生物可能对血压及相关疾病产生重大的正负影响。肠道中产生的细菌衍生代谢产物能够对身体的多种组织类型和器官产生广泛影响。显然,肠道生态失调所丧失的广泛代谢功能不太可能通过单一的代谢产物或菌株来补充。相反,细菌组合和伴随疗法将为控制高血压提供更全面的解决方案。本综述中认可的生物活性分子将为候选细菌的理想特性提供信息,并为未来高血压肠道微生物群的研究提供方向。